© 2020 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
All News
S2E5: The Womxn's Health Collaborative with Dr. Michal Elovitz
October 21, 2020
Senior Editor Angie DeRosa interviews Dr. Michal Elovitz, executive director of the recently formed Womxn’s Health Collaborative (WHC), a group whose mission is to empower women from diverse backgrounds to succeed and become leaders in science and health in the field of women’s health.
Do you recommend vaginal dilation to patients?
October 21, 2020
This week's poll focuses on vaginal dilation for treatment of various sexual concerns.
DNA sequencing technique may help prenatally detect NIHF
October 20, 2020
A new study in The New England Journal of Medicine used exome sequencing to analyze 127 fetuses with unexplained cases of nonimmune Hydrops fetalis.
The impact of extended newborn screening programs on inherited metabolic diseases
October 20, 2020
Despite the fact that extended newborn screenings have been used for more than 20 years, the impact of such screenings on long-term clinical outcomes among individuals who had inherited metabolic diseases is still relatively unknown.
October is Pregnancy and Infant Loss Awareness Month
October 20, 2020
Each year, approximately 24,000 babies are stillborn in the U.S, and as many as half of all pregnancies may end in miscarriage.
The Womxn's Health Collaborative with Dr. Michal Elovitz
October 19, 2020
The WHC is a response to the recent creation of a pregnancy think tank and years of fighting for equality.
Infectious complications after massive blood loss from gynecologic laparotomy
October 19, 2020
Massive intraoperative blood loss (MIBL) is strongly and independently linked to postoperative febrile morbidity following gynecologic laparotomy, according to a retrospective cohort study in the Journal of Obstetrics and Gynaecology Canada (JOGC).
What you missed this week on Contemporary OB/GYN
October 16, 2020
It was a very busy week for the Contemporary OB/GYN team.
Placental DNA may predict pregnancy complications
October 15, 2020
New research suggests that placental DNA may have potential as a biomarker for adverse pregnancy outcomes (APOs).